Cxcr4 antagonist and use thereof

Details Cxcr4 antagonist and use thereof Cxcr4 antagonist and use thereof

2003-08-26

2008-09-09

Gupta, Anish (Department: 1654)

Perfume compositions

Perfume compositions

Ring containing active ingredient

C512S002000, C530S326000, C530S327000, C530S333000

Reexamination Certificate

active

07423007

ABSTRACT:
The present invention provides preventive and/or therapeutic drugs for cancer and chronic rheumatoid arthritis which contain a peptide having a CXCR4 antagonism, its amide, its ester or its salt. Also, the present invention provides a novel peptide having a CXCR4 antagonism, its amide, its ester and its salt.

REFERENCES:
patent: 7138488 (2006-11-01), Fujii
patent: WO 95/10534 (1995-04-01), None
patent: WO 99/47158 (1999-09-01), None
patent: WO 01/38352 (2001-05-01), None
patent: WO 01/85196 (2001-11-01), None
patent: WO 02/20561 (2002-02-01), None
Tamamura H, Arakaki R, Funakoshi H, Imai M, Otaka A, Ibuka T, Nakashima H, Murakami T, Waki M, Matsumoto A,, Yamamoto N and Fujii N, Effective lowly cytotoxic analgos of an HIV-cell fusion inhibitor, T22([Tyr 5, 12, Lys7]-polyphemusin II), Bioorg Med Chem, 1998, 6: 231-238.
Tamamura H, Xu Y, Hattori T, Zhang X, Arakaki R, Kanbara K, Omagari A, Otaka A, Ibuka T, Yamamoto N, Nakashima H and Fujii N, A Low-Molecular-Weight Inhibitor against the Chemokine Receptor CXCR4: A Strong Anti-HIV Peptide T140, BBRC, 1998, 253: 877-882.
Introduction to Cancer from the Merck manual.
Clinical Aspects of Cancer from the Merck manual.
Auerbach R, Akhtar N, Lewis RL, Shinners BL, Angiogenesis assays: Problems and pitfalls, Cancer and Metastasis Reviews, 2000, 19: 167-172.
Gura T, Cancer Models: Systems for Identifying New Drugs Are Often Faulty, Science, 1997, 278(5340): 1041-1042, enclosed pp. 1-5.
Jain RK, Barriers to Drug Delivery in Solid Tumors, Scientific American, Jul. 1994, 58-65.
Rheumatoid Arthritis from the Merck Manual.
Tamamura H, Xu Younong, Hattori T, Zhang X, Arakaki R, Kanbara K, Omagari A, Otaka A, Ibuka T, Yamamoto N, Nakashima H, Fujii N, A Low-Molecular-Weight Inhibitor against chemokine receptor CXCR4: A strong Anti-HIV Peptide T140, Biochemical and Biophysical Research Communications, 1998, 253: 877-882.
Hatse et al., CXC-chemokine receptor 4 as a potential new therapeutic target for neuroblastoma and breast cancer,International Journal of Canc. Suppl,2002;13:349.
Hiramatsu et al., Synthesis of CXCR4 antagonists, T140 derivatives with improved biostability,and their SAR study.Peptide Science203;2002: 213-216 (Yamada, T, ed.).
Mori et al., Involvement of Stromal cell-Derived Factor 1 and CXCR4 receptor system in pancreatic cancer.Gastroenterology,2002;122(4),Suppl 1:A490. (Abstract T1608).
Tamamura et al., Downsizing of an HIV-cell fusion inhibitor, T22 ([Tyr5,12,Lys7]-polyphemusin II), with the maintenance of anti-HIV activity and solution structure.Bioorg Med Chem.1998, 6:473-9.
Tamamura et al., T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.FEBS Lett.(Aug. 28, 2003) 550:79-83.

Affiliated with

Also associated with

Rating

Cxcr4 antagonist and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cxcr4 antagonist and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cxcr4 antagonist and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3991863